Skip to main content

Table 2 Immunoreactive Score of Drp1, phospho-Drp1Ser637, CaMKI, phospho-CaMKIThr177 of the tumor and CA125 in relation to clinical factors of patients with ovarian cancer

From: Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer

Variable

Number of patients

Drp1

phospho-Drp1Ser637

CaMKI

phospho-CaMKIThr177

CA125

mean ± SE

p

mean ± SE

P

mean ± SE

p

mean ± SE

p

mean ± SE

p

Age

  < 55

20

10.05 ± 0.52

0.054

4.75 ± 0.66

0.053

9.25 ± 0.55

0.231

1.10 ± 0.24

0.311

792.3 ± 376.3

0.127

  ≥55

29

11.17 ± 0.35

 

6.45 ± 0.57

 

10.10 ± 0.44

 

0.86 ± 0.21

 

2141.0 ± 921.6

 

FIGO stage

 I-II

22

10.14 ± 0.46

0.050

5.00 ± 0.58

0.133

8.77 ± 0.52

0.011*

0.73 ± 0.19

0.122

340.8 ± 195.6

< 0.001*

 III-IV

27

11.19 ± 0.39

 

6.37 ± 0.63

 

10.56 ± 0.42

 

1.15 ± 0.24

 

2608.7 ± 987.8

 

Histology

 High-grade serous carcinoma

21

11.24 ± 0.43

0.098

6.62 ± 0.61

0.034*

9.71 ± 0.52

0.974

1.05 ± 0.26

0.502

2832.5 ± 1243.6

0.003*

 Non- high-grade serous carcinoma

28

10.32 ± 0.42

 

5.11 ± 0.61

 

9.79 ± 0.48

 

0.89 ± 0.20

 

658.9 ± 278.7

 

Completeness of surgical reduction

 Complete or optimal

39

10.39 ± 0.36

0.085

5.15 ± 0.46

0.006*

9.46 ± 0.40

0.116

1.03 ± 0.19

0.669

1753.4 ± 712.7

0.264

 Suboptimal

10

12.00 ± 0.00

 

8.10 ± 0.94

 

10.90 ± 0.57

 

0.70 ± 0.15

 

955.0 ± 281.5

 

Treatment response

 Responders

32

10.34 ± 0.40

0.209

5.00 ± 0.47

0.007*

9.25 ± 0.44

0.252

1.00 ± 0.23

0.732

1118 ± 381.5

0.117

 Non-responders

11

11.45 ± 0.55

 

7.82 ± 0.86

 

10.36 ± 0.70

 

0.82 ± 0.12

 

3183 ± 2231

 

Tumor progression

 No progression or platinum-sensitive

35

10.37 ± 0.38

0.056

5.40 ± 0.52

0.160

9.29 ± 0.43

0.030*

0.89 ± 0.16

0.633

1007.7 ± 300.8

0.101

 Platinum-resistant

14

11.57 ± 0.43

 

6.64 ± 0.80

 

10.93 ± 0.47

 

1.14 ± 0.39

 

3047.4 ± 1839

 
  1. * p < 0.05